Back To All Blogs

Setmelanotide for Obesity

Rhythm is currently recruiting for a Phase 2 clinical study of an investigational therapy on reduction of weight and hunger in individuals with Smith-Magenis Syndrome and rare genetic disorders of obesity. 

The study is enrolling individuals:

  • Age 6 years or older
  • With a confirmed diagnosis of Smith-Magenis Syndrome
  • With weight defined as
    • BMI of ≥ 30 kg/m for individuals ≥ 16 years of age
    • BMI of ≥ 95th percentile for individuals 6-16 years of age

Study participation includes:

  • 6 visits to the study center over a period of ~28 weeks
  • Daily study therapy administration during the treatment period (~16 weeks)
  • Completion of daily questionnaires
  • Medical examinations and safety monitoring (~once a month)
  • Blood tests

If you are interesting in learning more, please email SMStrialinfo@rhythmtx.com and please indicate the city, state, or country in which you reside.

ClinicalTrials.gov Identifier: NCT03013543